A
Alchemist
ALCHEM NSE
Alchemist
HealthcareNSE: ALCHEM BSE: 526707 Pharmaceuticals & Biotechnology
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Weaknesses
4- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -47.2% over past five years.
- Contingent liabilities of Rs.315 Cr.
- Company has high debtors of 9,597 days.
Growth Rate
Revenue Growth
-74% lower than
3Y
Net Income Growth
—
Quarterly Results
| Particulars | Dec 2012 | Mar 2013 | Jun 2013 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 388 | 360 | 409 | 9 | 6 | 6 | 6 | 6 | 5 | 3 | 1 | 1 | 1 |
| Expenses | 375 | 352 | 398 | -9 | 73 | 8 | 8 | 7 | 5 | 4 | 49 | 1 | 373 |
| Operating Profit | 12 | 8 | 11 | 18 | -67 | -2 | -2 | -1 | -1 | -1 | -48 | 0 | -372 |
| OPM % | 3.2% | 2.2% | 2.6% | 204% | -1116% | -25% | -43% | -16% | -14% | -52% | -3731% | 4.8% | -31800% |
| Other Income | 4 | 8 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 124 |
| Interest | 2 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 3 | 4 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| PBT | 12 | 9 | 8 | 16 | -69 | -3 | -4 | -3 | -2 | -3 | -50 | -1 | -250 |
| Tax % | 11% | 61% | 30% | -1% | 1% | 10% | -271% | 7% | 8% | -54% | -20% | 12% | -26% |
| Net Profit | 10 | 4 | 5 | 16 | -70 | -3 | 7 | -3 | -3 | -1 | -40 | -2 | -186 |
| EPS in Rs | 7.54 | 2.7 | 3.95 | 11.59 | -51.46 | -2.22 | 5.48 | -2.16 | -1.89 | -1.08 | -29.33 | -1.15 | -137 |
Profit & Loss
| Particulars | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 386 | 396 | 503 | 886 | 1,457 | 1,508 | 350 | 105 | 24 | 27 | 27 | 14 | 6 |
| Expenses | 355 | 364 | 468 | 852 | 1,417 | 1,475 | 375 | 138 | 53 | 36 | 80 | 65 | 427 |
| Operating Profit | 32 | 32 | 35 | 34 | 41 | 33 | -26 | -33 | -29 | -10 | -53 | -51 | -422 |
| OPM % | 8% | 8% | 7% | 3.8% | 2.8% | 2.2% | -7% | -32% | -121% | -36% | -199% | -354% | -7096% |
| Other Income | 3 | 3 | 1 | 12 | 16 | 14 | 14 | 13 | -69 | 3 | 1 | 0 | 124 |
| Interest | 8 | 7 | 4 | 4 | 7 | 4 | 5 | 5 | 2 | 2 | 1 | 1 | 0 |
| Depreciation | 8 | 8 | 10 | 11 | 12 | 15 | 23 | 26 | 8 | 8 | 7 | 7 | 6 |
| PBT | 19 | 20 | 22 | 31 | 38 | 28 | -39 | -52 | -108 | -16 | -61 | -58 | -304 |
| Tax % | 28% | 22% | 40% | 23% | 25% | 55% | -2% | 3% | -1% | 3% | -18% | -19% | — |
| Net Profit | 14 | 16 | 13 | 24 | 27 | 12 | -38 | -53 | -107 | -17 | -50 | -47 | -228 |
| EPS in Rs | 11.5 | 12.91 | 10.68 | 18.54 | 20.05 | 10.44 | -26.36 | -35.67 | -79.15 | -12.47 | -36.61 | -34.46 | -168 |
| Div. Payout % | 17% | 16% | 19% | 22% | 7% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Sep 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 12 | 12 | 12 | 13 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
| Reserves | 94 | 103 | 81 | 78 | 151 | 122 | 73 | 21 | -97 | -113 | -163 | -210 | -397 |
| Borrowings | 151 | 157 | 216 | 342 | 322 | 789 | 721 | 738 | 740 | 752 | 763 | 768 | 764 |
| Other Liabilities | 51 | 55 | 85 | 80 | 79 | 233 | 222 | 226 | 178 | 170 | 161 | 161 | 42 |
| Total Liabilities | 308 | 327 | 394 | 512 | 566 | 1,159 | 1,030 | 999 | 835 | 822 | 774 | 733 | 422 |
| Fixed Assets | 162 | 173 | 193 | 200 | 235 | 276 | 433 | 405 | 162 | 154 | 147 | 140 | 137 |
| CWIP | 40 | 45 | 74 | 135 | 201 | 202 | 27 | 19 | 0 | 0 | 0 | 0 | 0 |
| Investments | 24 | 24 | 23 | 2 | 2 | 2 | 2 | 2 | 171 | 169 | 169 | 169 | 169 |
| Other Assets | 82 | 85 | 104 | 176 | 128 | 679 | 568 | 574 | 503 | 500 | 459 | 424 | 116 |
| Total Assets | 308 | 327 | 394 | 512 | 566 | 1,159 | 1,030 | 999 | 835 | 822 | 774 | 733 | 422 |
Cash Flow
| Particulars | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 14 | 23 | 15 | 0 | 4 | -232 | -98 | -25 | -14 | -14 | -7 | -4 |
| Investing | -23 | -24 | -65 | 0 | -98 | -45 | -9 | -2 | 5 | 4 | -3 | 0 |
| Financing | 5 | -1 | 51 | 0 | 53 | 427 | -69 | 19 | 11 | 10 | 9 | 5 |
| Net Cash Flow | -4 | -2 | 1 | 0 | -40 | 150 | -175 | -8 | 1 | 0 | -1 | 0 |
| Free Cash Flow | -11 | -1 | -49 | 0 | -110 | -289 | -106 | -18 | -9 | -13 | -7 | -4 |
| CFO/OP | 45 | 71 | 58 | 0 | 26 | -667 | 380 | 75 | 49 | 148 | 13 | 8 |
Ratios
| Particulars | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 16 | 16 | 15 | 11 | 4 | 99 | 495 | 1,732 | 7,098 | 6,471 | 5,807 | 9,597 |
| Inventory Days | 26 | 32 | 31 | 17 | 11 | 12 | 56 | 230 | 114 | 36 | 19 | 20 |
| Days Payable | 17 | 21 | 10 | 4 | 2 | 38 | 176 | 828 | 2,641 | 2,554 | 2,430 | 4,894 |
| Cash Conversion Cycle | 25 | 27 | 36 | 25 | 12 | 73 | 375 | 1,134 | 4,572 | 3,952 | 3,397 | 4,723 |
| Working Capital Days | 14 | 16 | -16 | -4 | 5 | 67 | 358 | 1,224 | 4,735 | 4,355 | 3,702 | 5,772 |
| ROCE % | 11% | 10% | 9% | 9% | 10% | 5% | -3% | -5% | -5% | -2% | -9% | -10% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Alchemist insights
65 extracted metrics + investor summaries across FY09–FY26.
Documents
1
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
15h - Of Analyst / Institutional Investor meeting under the SEBI (LODR), Regulations 2015 15h - Of Analyst / Institutional Investor meeting under the SEBI (LODR), Regulations 2015
2
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
5 Feb - Transcript of the earnings conference call for the Q3FY26 ended on December 31, 2025 5 Feb - Transcript of the earnings conference call for the Q3FY26 ended on December 31, 2025
3
Announcement under Regulation 30 (LODR)-Investor Presentation
30 Jan - Submission of Investor Presentation under Regulation 30 of the SEBI (LODR) Regulations, 2015. 30 Jan - Submission of Investor Presentation under Regulation 30 of the SEBI (LODR) Regulations, 2015.
5
The Board Has Fixed 06.02.2026 As The Record Date For The Purpose Of Third Interim Dividend For FY 2025-26 Declared At Its Meeting Held On 30.01.2026.
30 Jan - Unaudited Q3/Q9 results; quarter PAT Rs2,058.58L, YTD PAT Rs6,368.23L; interim dividend Rs0.45/share; record date 06-Feb-2026. 30 Jan - Unaudited Q3/Q9 results; quarter PAT Rs2,058.58L, YTD PAT Rs6,368.23L; interim dividend Rs0.45/share; record date 06-Feb-2026.
2
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer 6 Feb 2021
Company Update
Frequently Asked Questions about Alchemist
What does Alchemist Ltd do?
Alchemist is engaged in the business of Agriculture and allied activities comprising of floriculture and manufacturing of wire mesh for poultry industry and trading of chemicals and pharmaceutical formulations.
Where is Alchemist Ltd (ALCHEM) listed?
Alchemist Ltd trades as ALCHEM on the NSE and under code 526707 on the BSE.
Which sector does Alchemist Ltd belong to?
Alchemist Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
Company Information
Alchemist is engaged in the business of Agriculture and allied activities comprising of floriculture and manufacturing of wire mesh for poultry industry and trading of chemicals and pharmaceutical formulations.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ALCHEM.md for Alchemist Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.